BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Popov Y, Patsenker E, Fickert P, Trauner M, Schuppan D. Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol. 2005;43:1045-1054. [PMID: 16223543 DOI: 10.1016/j.jhep.2005.06.025] [Cited by in Crossref: 171] [Cited by in F6Publishing: 164] [Article Influence: 10.1] [Reference Citation Analysis]
Number Citing Articles
1 Hobbie KR, DeAngelo AB, George MH, Law JM. Neoplastic and nonneoplastic liver lesions induced by dimethylnitrosamine in Japanese medaka fish. Vet Pathol 2012;49:372-85. [PMID: 21724976 DOI: 10.1177/0300985811409443] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
2 Popov Y, Patsenker E, Stickel F, Zaks J, Bhaskar KR, Niedobitek G, Kolb A, Friess H, Schuppan D. Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J Hepatol 2008;48:453-64. [PMID: 18221819 DOI: 10.1016/j.jhep.2007.11.021] [Cited by in Crossref: 120] [Cited by in F6Publishing: 121] [Article Influence: 8.6] [Reference Citation Analysis]
3 Peng ZW, Ikenaga N, Liu SB, Sverdlov DY, Vaid KA, Dixit R, Weinreb PH, Violette S, Sheppard D, Schuppan D, Popov Y. Integrin αvβ6 critically regulates hepatic progenitor cell function and promotes ductular reaction, fibrosis, and tumorigenesis. Hepatology 2016;63:217-32. [PMID: 26448099 DOI: 10.1002/hep.28274] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 8.6] [Reference Citation Analysis]
4 Tardelli M, Bruschi FV, Fuchs CD, Claudel T, Auer N, Kunczer V, Ronda OAHO, Verkade HJ, Stojakovic T, Scharnagl H, Trauner M. Absence of Adiponutrin (PNPLA3) and Monoacylglycerol Lipase Synergistically Increases Weight Gain and Aggravates Steatohepatitis in Mice. Int J Mol Sci 2021;22:2126. [PMID: 33672787 DOI: 10.3390/ijms22042126] [Reference Citation Analysis]
5 Ziol M, Barbu V, Rosmorduc O, Frassati-Biaggi A, Barget N, Hermelin B, Scheffer GL, Bennouna S, Trinchet JC, Beaugrand M, Ganne-Carrié N. ABCB4 heterozygous gene mutations associated with fibrosing cholestatic liver disease in adults. Gastroenterology 2008;135:131-41. [PMID: 18482588 DOI: 10.1053/j.gastro.2008.03.044] [Cited by in Crossref: 110] [Cited by in F6Publishing: 90] [Article Influence: 7.9] [Reference Citation Analysis]
6 Stofan M, Guo GL. Bile Acids and FXR: Novel Targets for Liver Diseases. Front Med (Lausanne) 2020;7:544. [PMID: 33015098 DOI: 10.3389/fmed.2020.00544] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
7 Reiter FP, Hohenester S, Nagel JM, Wimmer R, Artmann R, Wottke L, Makeschin MC, Mayr D, Rust C, Trauner M. 1,25-(OH)2-vitamin D3 prevents activation of hepatic stellate cells in vitro and ameliorates inflammatory liver damage but not fibrosis in the Abcb4(-/-) model. Biochem Biophys Res Commun. 2015;459:227-233. [PMID: 25712522 DOI: 10.1016/j.bbrc.2015.02.074] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
8 Næss S, Shiryaev A, Hov JR, Franke A, Karlsen TH. Genetics in primary sclerosing cholangitis. Clin Res Hepatol Gastroenterol. 2012;36:325-333. [PMID: 22554879 DOI: 10.1016/j.clinre.2012.02.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
9 Sato K, Meng F, Giang T, Glaser S, Alpini G. Mechanisms of cholangiocyte responses to injury. Biochim Biophys Acta Mol Basis Dis 2018;1864:1262-9. [PMID: 28648950 DOI: 10.1016/j.bbadis.2017.06.017] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
10 Meng F, Kennedy L, Hargrove L, Demieville J, Jones H, Madeka T, Karstens A, Chappell K, Alpini G, Sybenga A, Invernizzi P, Bernuzzi F, DeMorrow S, Francis H. Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2-/- mice and human primary sclerosing cholangitis. Lab Invest 2018;98:1465-77. [PMID: 30143751 DOI: 10.1038/s41374-018-0101-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
11 Tardelli M. Monoacylglycerol lipase reprograms lipid precursors signaling in liver disease. World J Gastroenterol 2020; 26(25): 3577-3585 [PMID: 32742127 DOI: 10.3748/wjg.v26.i25.3577] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Martin CR, Zaman MM, Ketwaroo GA, Bhutta AQ, Coronel E, Popov Y, Schuppan D, Freedman SD. CFTR dysfunction predisposes to fibrotic liver disease in a murine model. Am J Physiol Gastrointest Liver Physiol 2012;303:G474-81. [PMID: 22679000 DOI: 10.1152/ajpgi.00055.2012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
13 Trauner M, Fickert P, Halilbasic E, Moustafa T. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases. Wien Med Wochenschr. 2008;158:542-548. [PMID: 18998069 DOI: 10.1007/s10354-008-0592-1] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 5.6] [Reference Citation Analysis]
14 Gutiérrez-de-Juan V, López de Davalillo S, Fernández-Ramos D, Barbier-Torres L, Zubiete-Franco I, Fernández-Tussy P, Simon J, Lopitz-Otsoa F, de Las Heras J, Iruzubieta P, Arias-Loste MT, Villa E, Crespo J, Andrade R, Lucena MI, Varela-Rey M, Lu SC, Mato JM, Delgado TC, Martínez-Chantar ML. A morphological method for ammonia detection in liver. PLoS One 2017;12:e0173914. [PMID: 28319158 DOI: 10.1371/journal.pone.0173914] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
15 Baghdasaryan A, Claudel T, Gumhold J, Silbert D, Adorini L, Roda A, Vecchiotti S, Gonzalez FJ, Schoonjans K, Strazzabosco M. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO-3 output. Hepatology. 2011;54:1303-1312. [PMID: 22006858 DOI: 10.1002/hep.24537] [Cited by in Crossref: 149] [Cited by in F6Publishing: 131] [Article Influence: 13.5] [Reference Citation Analysis]
16 Baghdasaryan A, Claudel T, Kosters A, Gumhold J, Silbert D, Thüringer A, Leski K, Fickert P, Karpen SJ, Trauner M. Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation. Gut 2010;59:521-30. [PMID: 20332524 DOI: 10.1136/gut.2009.186528] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 4.4] [Reference Citation Analysis]
17 Kennedy L, Meadows V, Demieville J, Hargrove L, Virani S, Glaser S, Zhou T, Rinehart E, Jaeger V, Kyritsi K, Pham L, Alpini G, Francis H. Biliary damage and liver fibrosis are ameliorated in a novel mouse model lacking l-histidine decarboxylase/histamine signaling. Lab Invest 2020;100:837-48. [PMID: 32054995 DOI: 10.1038/s41374-020-0405-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
18 Yang T, Poenisch M, Khanal R, Hu Q, Dai Z, Li R, Song G, Yuan Q, Yao Q, Shen X, Taubert R, Engel B, Jaeckel E, Vogel A, Falk CS, Schambach A, Gerovska D, Araúzo-Bravo MJ, Vondran FWR, Cantz T, Horscroft N, Balakrishnan A, Chevessier F, Ott M, Sharma AD. Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model. J Hepatol 2021:S0168-8278(21)02006-7. [PMID: 34453962 DOI: 10.1016/j.jhep.2021.08.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Liu SP, Bian ZH, Zhao ZB, Wang J, Zhang W, Leung PSC, Li L, Lian ZX. Animal Models of Autoimmune Liver Diseases: a Comprehensive Review. Clin Rev Allergy Immunol 2020;58:252-71. [PMID: 32076943 DOI: 10.1007/s12016-020-08778-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
20 Mende S, Schulte S, Strack I, Hunt H, Odenthal M, Pryymachuck G, Quasdorff M, Demir M, Nierhoff D, Dienes H, Goeser T, Steffen H, Töx U. Telmisartan Plus Propranolol Improves Liver Fibrosis and Bile Duct Proliferation in the PSC-Like Abcb4−/− Mouse Model. Dig Dis Sci 2013;58:1271-81. [DOI: 10.1007/s10620-012-2499-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
21 Zhang CY, Yuan WG, He P, Lei JH, Wang CX. Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets. World J Gastroenterol 2016; 22(48): 10512-10522 [PMID: 28082803 DOI: 10.3748/wjg.v22.i48.10512] [Cited by in CrossRef: 198] [Cited by in F6Publishing: 182] [Article Influence: 33.0] [Reference Citation Analysis]
22 Nakken KE, Nygård S, Haaland T, Berge KE, Arnkvaern K, Ødegaard A, Labori KJ, Raeder MG. Multiple inflammatory-, tissue remodelling- and fibrosis genes are differentially transcribed in the livers of Abcb4 (-/ - ) mice harbouring chronic cholangitis. Scand J Gastroenterol 2007;42:1245-55. [PMID: 17852852 DOI: 10.1080/00365520701320521] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
23 Pradhan-Sundd T, Kosar K, Saggi H, Zhang R, Vats R, Cornuet P, Green S, Singh S, Zeng G, Sundd P, Nejak-Bowen K. Wnt/β-Catenin Signaling Plays a Protective Role in the Mdr2 Knockout Murine Model of Cholestatic Liver Disease. Hepatology 2020;71:1732-49. [PMID: 31489648 DOI: 10.1002/hep.30927] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
24 Krishnan A, Katsumi T, Guicciardi ME, Azad AI, Ozturk NB, Trussoni CE, Gores GJ. Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Deficiency Promotes the Ductular Reaction, Macrophage Accumulation, and Hepatic Fibrosis in the Abcb4-/- Mouse. Am J Pathol 2020;190:1284-97. [PMID: 32240619 DOI: 10.1016/j.ajpath.2020.02.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
25 Martínez AK, Maroni L, Marzioni M, Ahmed ST, Milad M, Ray D, Alpini G, Glaser SS. Mouse models of liver fibrosis mimic human liver fibrosis of different etiologies. Curr Pathobiol Rep 2014;2:143-53. [PMID: 25396098 DOI: 10.1007/s40139-014-0050-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
26 Hartwig V, Dewidar B, Lin T, Dropmann A, Ganss C, Kluth MA, Tappenbeck N, Tietze L, Christ B, Frank M, Vogelmann R, Ebert MPA, Dooley S. Human skin-derived ABCB5+ stem cell injection improves liver disease parameters in Mdr2KO mice. Arch Toxicol 2019;93:2645-60. [DOI: 10.1007/s00204-019-02533-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
27 Kopec AK, Joshi N, Luyendyk JP. Role of hemostatic factors in hepatic injury and disease: animal models de-liver. J Thromb Haemost. 2016;14:1337-1349. [PMID: 27060337 DOI: 10.1111/jth.13327] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
28 Patsenker E, Wilkens L, Banz V, Osterreicher CH, Weimann R, Eisele S, Keogh A, Stroka D, Zimmermann A, Stickel F. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma. J Hepatol 2010;52:362-9. [PMID: 20137822 DOI: 10.1016/j.jhep.2009.12.006] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
29 Rajapaksha IG, Mak KY, Huang P, Burrell LM, Angus PW, Herath CB. The small molecule drug diminazene aceturate inhibits liver injury and biliary fibrosis in mice. Sci Rep 2018;8:10175. [PMID: 29977014 DOI: 10.1038/s41598-018-28490-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
30 Cai SY, Mennone A, Soroka CJ, Boyer JL. Altered expression and function of canalicular transporters during early development of cholestatic liver injury in Abcb4-deficient mice. Am J Physiol Gastrointest Liver Physiol 2014;306:G670-6. [PMID: 24481602 DOI: 10.1152/ajpgi.00334.2013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
31 Ikenaga N, Peng ZW, Vaid KA, Liu SB, Yoshida S, Sverdlov DY, Mikels-Vigdal A, Smith V, Schuppan D, Popov YV. Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal. Gut 2017;66:1697-708. [PMID: 28073888 DOI: 10.1136/gutjnl-2016-312473] [Cited by in Crossref: 135] [Cited by in F6Publishing: 127] [Article Influence: 27.0] [Reference Citation Analysis]
32 Karlsen TH, Schrumpf E, Boberg KM. Update on primary sclerosing cholangitis. Dig Liver Dis. 2010;42:390-400. [PMID: 20172772 DOI: 10.1016/j.dld.2010.01.011] [Cited by in Crossref: 83] [Cited by in F6Publishing: 72] [Article Influence: 6.9] [Reference Citation Analysis]
33 Friedman SL. Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol. 2010;7:425-436. [PMID: 20585339 DOI: 10.1038/nrgastro. 2010.97] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Meadows V, Kennedy L, Hargrove L, Demieville J, Meng F, Virani S, Reinhart E, Kyritsi K, Invernizzi P, Yang Z, Wu N, Liangpunsakul S, Alpini G, Francis H. Downregulation of hepatic stem cell factor by Vivo-Morpholino treatment inhibits mast cell migration and decreases biliary damage/senescence and liver fibrosis in Mdr2-/- mice. Biochim Biophys Acta Mol Basis Dis 2019;1865:165557. [PMID: 31521820 DOI: 10.1016/j.bbadis.2019.165557] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
35 Mimche PN, Lee CM, Mimche SM, Thapa M, Grakoui A, Henkemeyer M, Lamb TJ. EphB2 receptor tyrosine kinase promotes hepatic fibrogenesis in mice via activation of hepatic stellate cells. Sci Rep 2018;8:2532. [PMID: 29416088 DOI: 10.1038/s41598-018-20926-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
36 Hochrath K, Krawczyk M, Goebel R, Langhirt M, Rathkolb B, Micklich K, Rozman J, Horsch M, Beckers J, Klingenspor M, Fuchs H, Gailus-Durner V, Wolf E, Acalovschi M, Volmer DA, Hrabě de Angelis M, Lammert F. The hepatic phosphatidylcholine transporter ABCB4 as modulator of glucose homeostasis. FASEB J 2012;26:5081-91. [PMID: 22982378 DOI: 10.1096/fj.12-209379] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
37 Mederacke I, Hsu CC, Troeger JS, Huebener P, Mu X, Dapito DH, Pradere JP, Schwabe RF. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun. 2013;4:2823. [PMID: 24264436 DOI: 10.1038/ncomms3823] [Cited by in Crossref: 621] [Cited by in F6Publishing: 606] [Article Influence: 77.6] [Reference Citation Analysis]
38 Barashi N, Weiss ID, Wald O, Wald H, Beider K, Abraham M, Klein S, Goldenberg D, Axelrod J, Pikarsky E. Inflammation-induced hepatocellular carcinoma is dependent on CCR5 in mice. Hepatology. 2013;58:1021-1030. [PMID: 23526353 DOI: 10.1002/hep.26403] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 5.4] [Reference Citation Analysis]
39 Reiter FP, Wimmer R, Wottke L, Artmann R, Nagel JM, Carranza MO, Mayr D, Rust C, Fickert P, Trauner M, Gerbes AL, Hohenester S, Denk GU. Role of interleukin-1 and its antagonism of hepatic stellate cell proliferation and liver fibrosis in the Abcb4-/- mouse model. World J Hepatol 2016; 8(8): 401-410 [PMID: 27004088 DOI: 10.4254/wjh.v8.i8.401] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
40 Lefkowitch JH. Hepatobiliary pathology. Curr Opin Gastroenterol 2007;23:221-31. [PMID: 17414836 DOI: 10.1097/MOG.0b013e3280adc92e] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
41 Schuppan D, Ashfaq-Khan M, Yang AT, Kim YO. Liver fibrosis: Direct antifibrotic agents and targeted therapies. Matrix Biol. 2018;68-69:435-451. [PMID: 29656147 DOI: 10.1016/j.matbio.2018.04.006] [Cited by in Crossref: 144] [Cited by in F6Publishing: 140] [Article Influence: 36.0] [Reference Citation Analysis]
42 Cingolani F, Liu Y, Shen Y, Wen J, Farris AB, Czaja MJ. Redundant Functions of ERK1 and ERK2 Maintain Mouse Liver Homeostasis Through Down‐Regulation of Bile Acid Synthesis. Hepatology Communications. [DOI: 10.1002/hep4.1867] [Reference Citation Analysis]
43 Oude Elferink RP, Paulusma CC. Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein). Pflugers Arch. 2007;453:601-610. [PMID: 16622704 DOI: 10.1007/s00424-006-0062-9] [Cited by in Crossref: 188] [Cited by in F6Publishing: 159] [Article Influence: 11.8] [Reference Citation Analysis]
44 Weiskirchen R, Meurer SK, Liedtke C, Huber M. Mast Cells in Liver Fibrogenesis. Cells 2019;8:E1429. [PMID: 31766207 DOI: 10.3390/cells8111429] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
45 Patsenker E, Popov Y, Wiesner M, Goodman SL, Schuppan D. Pharmacological inhibition of the vitronectin receptor abrogates PDGF-BB-induced hepatic stellate cell migration and activation in vitro. J Hepatol 2007;46:878-87. [PMID: 17258347 DOI: 10.1016/j.jhep.2006.11.011] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 2.6] [Reference Citation Analysis]
46 Barash H, Gross E, Edrei Y, Pappo O, Spira G, Vlodavsky I, Galun E, Matot I, Abramovitch R. Functional magnetic resonance imaging monitoring of pathological changes in rodent livers during hyperoxia and hypercapnia. Hepatology. 2008;48:1232-1241. [PMID: 18629804 DOI: 10.1002/hep.22394] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
47 Buko VU, Lukivskaya OY, Naruta EE, Belonovskaya EB, Tauschel HD. Protective Effects of Norursodeoxycholic Acid Versus Ursodeoxycholic Acid on Thioacetamide-induced Rat Liver Fibrosis. J Clin Exp Hepatol 2014;4:293-301. [PMID: 25755576 DOI: 10.1016/j.jceh.2014.02.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
48 Li J, Dawson PA. Animal models to study bile acid metabolism. Biochim Biophys Acta Mol Basis Dis 2019;1865:895-911. [PMID: 29782919 DOI: 10.1016/j.bbadis.2018.05.011] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 9.3] [Reference Citation Analysis]
49 Berkhout L, Barikbin R, Schiller B, Ravichandran G, Krech T, Neumann K, Sass G, Tiegs G. Deletion of tumour necrosis factor α receptor 1 elicits an increased TH17 immune response in the chronically inflamed liver. Sci Rep 2019;9:4232. [PMID: 30862875 DOI: 10.1038/s41598-019-40324-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
50 Eksteen B. Advances and controversies in the pathogenesis and management of primary sclerosing cholangitis. Br Med Bull. 2014;110:89-98. [PMID: 24795363 DOI: 10.1093/bmb/ldu008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
51 Jones H, Hargrove L, Kennedy L, Meng F, Graf-Eaton A, Owens J, Alpini G, Johnson C, Bernuzzi F, Demieville J, DeMorrow S, Invernizzi P, Francis H. Inhibition of mast cell-secreted histamine decreases biliary proliferation and fibrosis in primary sclerosing cholangitis Mdr2(-/-) mice. Hepatology 2016;64:1202-16. [PMID: 27351144 DOI: 10.1002/hep.28704] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 6.8] [Reference Citation Analysis]
52 Kong XY, Kase ET, Herskedal A, Schjalm C, Damme M, Nesset CK, Thoresen GH, Rustan AC, Eskild W. Lack of the Lysosomal Membrane Protein, GLMP, in Mice Results in Metabolic Dysregulation in Liver. PLoS One 2015;10:e0129402. [PMID: 26047317 DOI: 10.1371/journal.pone.0129402] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
53 Mariotti V, Strazzabosco M, Fabris L, Calvisi DF. Animal models of biliary injury and altered bile acid metabolism. Biochim Biophys Acta Mol Basis Dis. 2018;1864:1254-1261. [PMID: 28709963 DOI: 10.1016/j.bbadis.2017.06.027] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 10.2] [Reference Citation Analysis]
54 Pollheimer MJ, Fickert P. Animal Models in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Clinic Rev Allerg Immunol 2015;48:207-17. [DOI: 10.1007/s12016-014-8442-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
55 Liu Y, Meyer C, Xu C, Weng H, Hellerbrand C, ten Dijke P, Dooley S. Animal models of chronic liver diseases. Am J Physiol Gastrointest Liver Physiol. 2013;304:G449-G468. [PMID: 23275613 DOI: 10.1152/ajpgi.00199.2012] [Cited by in Crossref: 118] [Cited by in F6Publishing: 112] [Article Influence: 11.8] [Reference Citation Analysis]
56 Maroni L, Haibo B, Ray D, Zhou T, Wan Y, Meng F, Marzioni M, Alpini G. Functional and structural features of cholangiocytes in health and disease. Cell Mol Gastroenterol Hepatol 2015;1:368-80. [PMID: 26273695 DOI: 10.1016/j.jcmgh.2015.05.005] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 7.6] [Reference Citation Analysis]
57 Chen YH, Lan T, Li J, Qiu CH, Wu T, Gou HJ, Lu MQ. Gardenia jasminoides attenuates hepatocellular injury and fibrosis in bile duct-ligated rats and human hepatic stellate cells. World J Gastroenterol 2012; 18(48): 7158-7165 [PMID: 23326120 DOI: 10.3748/wjg.v18.i48.7158] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
58 Lamireau T, Bouchard G, Yousef IM, Clouzeau-Girard H, Rosenbaum J, Desmoulière A, Tuchweber B. Dietary lecithin protects against cholestatic liver disease in cholic acid-fed Abcb4- deficient mice. Pediatr Res 2007;61:185-90. [PMID: 17237720 DOI: 10.1203/pdr.0b013e31802d7780] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
59 Popov Y. Mouse model of primary biliary cirrhosis with progressive fibrosis: are we there yet? Hepatology. 2013;57:429-431. [PMID: 22815060 DOI: 10.1002/hep.25969] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
60 Henkel C, Roderfeld M, Weiskirchen R, Berres ML, Hillebrandt S, Lammert F, Meyer HE, Stühler K, Graf J, Roeb E. Changes of the hepatic proteome in murine models for toxically induced fibrogenesis and sclerosing cholangitis. Proteomics 2006;6:6538-48. [PMID: 17109383 DOI: 10.1002/pmic.200600580] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.3] [Reference Citation Analysis]
61 Popov Y, Sverdlov DY, Bhaskar KR, Sharma AK, Millonig G, Patsenker E, Krahenbuhl S, Krahenbuhl L, Schuppan D. Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis. Am J Physiol Gastrointest Liver Physiol. 2010;298:G323-G334. [PMID: 20056896 DOI: 10.1152/ajpgi.00394.2009] [Cited by in Crossref: 89] [Cited by in F6Publishing: 94] [Article Influence: 7.4] [Reference Citation Analysis]
62 Joshi N, Ray JL, Kopec AK, Luyendyk JP. Dose-dependent effects of alpha-naphthylisothiocyanate disconnect biliary fibrosis from hepatocellular necrosis. J Biochem Mol Toxicol 2017;31:1-7. [PMID: 27605088 DOI: 10.1002/jbt.21834] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
63 Hull LC, Farrell D, Grodzinski P. Highlights of recent developments and trends in cancer nanotechnology research--view from NCI Alliance for Nanotechnology in Cancer. Biotechnol Adv 2014;32:666-78. [PMID: 23948249 DOI: 10.1016/j.biotechadv.2013.08.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
64 Schuppan D, Pinzani M. Anti-fibrotic therapy: lost in translation? J Hepatol 2012;56 Suppl 1:S66-74. [PMID: 22300467 DOI: 10.1016/S0168-8278(12)60008-7] [Cited by in Crossref: 73] [Cited by in F6Publishing: 37] [Article Influence: 7.3] [Reference Citation Analysis]
65 Schuppan D, Popov Y. Rationale and targets for antifibrotic therapies. Gastroenterol Clin Biol 2009;33:949-57. [PMID: 19726145 DOI: 10.1016/j.gcb.2009.07.021] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
66 Cooper TK, Zhong Q, Krawczyk M, Tae HJ, Müller GA, Schubert R, Myers LA, Dietz HC, Talan MI, Briest W. The haploinsufficient Col3a1 mouse as a model for vascular Ehlers-Danlos syndrome. Vet Pathol 2010;47:1028-39. [PMID: 20587693 DOI: 10.1177/0300985810374842] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
67 Friedman SL. Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol 2010;7:425-36. [DOI: 10.1038/nrgastro.2010.97] [Cited by in Crossref: 377] [Cited by in F6Publishing: 379] [Article Influence: 31.4] [Reference Citation Analysis]
68 Aoki H, Aoki M, Yang J, Katsuta E, Mukhopadhyay P, Ramanathan R, Woelfel IA, Wang X, Spiegel S, Zhou H, Takabe K. Murine model of long-term obstructive jaundice. J Surg Res. 2016;206:118-125. [PMID: 27916350 DOI: 10.1016/j.jss.2016.07.020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
69 Popov Y, Schuppan D. Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology. 2009;50:1294-1306. [PMID: 19711424 DOI: 10.1002/hep.23123] [Cited by in Crossref: 214] [Cited by in F6Publishing: 222] [Article Influence: 16.5] [Reference Citation Analysis]
70 Roderfeld M, Rath T, Voswinckel R, Dierkes C, Dietrich H, Zahner D, Graf J, Roeb E. Bone marrow transplantation demonstrates medullar origin of CD34+ fibrocytes and ameliorates hepatic fibrosis in Abcb4-/- mice. Hepatology. 2010;51:267-276. [PMID: 19827165 DOI: 10.1002/hep.23274] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 4.7] [Reference Citation Analysis]
71 Westra IM, Pham BT, Groothuis GMM, Olinga P. Evaluation of fibrosis in precision-cut tissue slices. Xenobiotica 2012;43:98-112. [DOI: 10.3109/00498254.2012.723151] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
72 Baghdasaryan A, Fickert P, Fuchsbichler A, Silbert D, Gumhold J, Hörl G, Langner C, Moustafa T, Halilbasic E, Claudel T, Trauner M. Role of hepatic phospholipids in development of liver injury in Mdr2 (Abcb4) knockout mice: Phospholipids and liver injury in Mdr2 knockout mice. Liver International 2008;28:948-58. [DOI: 10.1111/j.1478-3231.2008.01758.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
73 Claveria-Cabello A, Colyn L, Uriarte I, Latasa MU, Arechederra M, Herranz JM, Alvarez L, Urman JM, Martinez-Chantar ML, Banales JM, Sangro B, Rombouts K, Oyarzabal J, Marin JJG, Berasain C, Avila MA, Fernandez-Barrena MG. Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis. Cancers (Basel) 2020;12:E3748. [PMID: 33322158 DOI: 10.3390/cancers12123748] [Reference Citation Analysis]
74 van Dijk F, Teekamp N, Beljaars L, Post E, Zuidema J, Steendam R, Kim Y, Frijlink H, Schuppan D, Poelstra K, Hinrichs W, Olinga P. Pharmacokinetics of a sustained release formulation of PDGFβ-receptor directed carrier proteins to target the fibrotic liver. Journal of Controlled Release 2018;269:258-65. [DOI: 10.1016/j.jconrel.2017.11.029] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
75 Sobbe A, Bridle KR, Jaskowski L, de Guzman CE, Santrampurwala N, Clouston AD, Campbell CM, Subramaniam VN, Crawford DH. Inconsistent hepatic antifibrotic effects with the iron chelator deferasirox. J Gastroenterol Hepatol. 2015;30:638-645. [PMID: 25168203 DOI: 10.1111/jgh.12720] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
76 Patsenker E, Stoll M, Millonig G, Agaimy A, Wissniowski T, Schneider V, Mueller S, Brenneisen R, Seitz HK, Ocker M. Cannabinoid receptor type I modulates alcohol-induced liver fibrosis. Mol Med. 2011;17:1285-1294. [PMID: 21863215 DOI: 10.2119/molmed.2011.00149] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
77 Wei G, Cao J, Huang P, An P, Badlani D, Vaid KA, Zhao S, Wang DQ, Zhuo J, Yin L, Frassetto A, Markel A, Presnyak V, Gandham S, Hua S, Lukacs C, Finn PF, Giangrande PH, Martini PGV, Popov YV. Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4-/- mouse model of PFIC3. J Hepatol 2021;74:1416-28. [PMID: 33340584 DOI: 10.1016/j.jhep.2020.12.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
78 de Meijer VE, Sverdlov DY, Popov Y, Le HD, Meisel JA, Nosé V, Schuppan D, Puder M. Broad-spectrum matrix metalloproteinase inhibition curbs inflammation and liver injury but aggravates experimental liver fibrosis in mice. PLoS One 2010;5:e11256. [PMID: 20593020 DOI: 10.1371/journal.pone.0011256] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 3.8] [Reference Citation Analysis]
79 Bhatia SN, Underhill GH, Zaret KS, Fox IJ. Cell and tissue engineering for liver disease. Sci Transl Med. 2014;6:245sr2. [PMID: 25031271 DOI: 10.1126/scitranslmed.3005975] [Cited by in Crossref: 178] [Cited by in F6Publishing: 167] [Article Influence: 25.4] [Reference Citation Analysis]
80 Friedman SL, Sheppard D, Duffield JS, Violette S. Therapy for Fibrotic Diseases: Nearing the Starting Line. Science Translational Medicine 2013;5:167sr1-167sr1. [DOI: 10.1126/scitranslmed.3004700] [Cited by in Crossref: 402] [Cited by in F6Publishing: 401] [Article Influence: 44.7] [Reference Citation Analysis]
81 Locatelli L, Cadamuro M, Spirlì C, Fiorotto R, Lecchi S, Morell CM, Popov Y, Scirpo R, De Matteis M, Amenduni M. Macrophage recruitment by fibrocystin-defective biliary epithelial cells promotes portal fibrosis in congenital hepatic fibrosis. Hepatology. 2016;63:965-982. [PMID: 26645994 DOI: 10.1002/hep.28382] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 7.8] [Reference Citation Analysis]
82 Maggs JR, Chapman RW. Sclerosing cholangitis: . Current Opinion in Gastroenterology 2007;23:310-6. [DOI: 10.1097/mog.0b013e32805867e6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
83 Patsenker E, Popov Y, Stickel F, Schneider V, Ledermann M, Sägesser H, Niedobitek G, Goodman SL, Schuppan D. Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology. 2009;50:1501-1511. [PMID: 19725105 DOI: 10.1002/hep.23144] [Cited by in Crossref: 116] [Cited by in F6Publishing: 114] [Article Influence: 8.9] [Reference Citation Analysis]
84 Lukivskaya O, Patsenker E, Lis R, Buko VU. Inhibition of inducible nitric oxide synthase activity prevents liver recovery in rat thioacetamide-induced fibrosis reversal. Eur J Clin Invest. 2008;38:317-325. [PMID: 18380797 DOI: 10.1111/j.1365-2362.2008.01941.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
85 Kim YO, Popov Y, Schuppan D. Optimized Mouse Models for Liver Fibrosis. Methods Mol Biol. 2017;1559:279-296. [PMID: 28063051 DOI: 10.1007/978-1-4939-6786-5_19] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
86 Bridle KR, Sobbe AL, de Guzman CE, Santrampurwala N, Jaskowski LA, Clouston AD, Campbell CM, Nathan Subramaniam V, Crawford DH. Lack of efficacy of mTOR inhibitors and ACE pathway inhibitors as antifibrotic agents in evolving and established fibrosis in Mdr2−/− mice. Liver Int 2015;35:1451-63. [DOI: 10.1111/liv.12494] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
87 Li X, Liu R, Huang Z, Gurley EC, Wang X, Wang J, He H, Yang H, Lai G, Zhang L, Bajaj JS, White M, Pandak WM, Hylemon PB, Zhou H. Cholangiocyte-derived exosomal long noncoding RNA H19 promotes cholestatic liver injury in mouse and humans. Hepatology 2018;68:599-615. [PMID: 29425397 DOI: 10.1002/hep.29838] [Cited by in Crossref: 59] [Cited by in F6Publishing: 64] [Article Influence: 14.8] [Reference Citation Analysis]
88 Kuramitsu K, Sverdlov DY, Liu SB, Csizmadia E, Burkly L, Schuppan D, Hanto DW, Otterbein LE, Popov Y. Failure of fibrotic liver regeneration in mice is linked to a severe fibrogenic response driven by hepatic progenitor cell activation. Am J Pathol. 2013;183:182-194. [PMID: 23680654 DOI: 10.1016/j.ajpath.2013.03.018] [Cited by in Crossref: 66] [Cited by in F6Publishing: 76] [Article Influence: 7.3] [Reference Citation Analysis]
89 Mariotti V, Cadamuro M, Spirli C, Fiorotto R, Strazzabosco M, Fabris L. Animal models of cholestasis: An update on inflammatory cholangiopathies. Biochim Biophys Acta Mol Basis Dis 2019;1865:954-64. [PMID: 30398152 DOI: 10.1016/j.bbadis.2018.07.025] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
90 Ceci L, Francis H, Zhou T, Giang T, Yang Z, Meng F, Wu N, Kennedy L, Kyritsi K, Meadows V, Wu C, Liangpunsakul S, Franchitto A, Sybenga A, Ekser B, Mancinelli R, Onori P, Gaudio E, Glaser S, Alpini G. Knockout of the Tachykinin Receptor 1 in the Mdr2-/- (Abcb4-/-) Mouse Model of Primary Sclerosing Cholangitis Reduces Biliary Damage and Liver Fibrosis. Am J Pathol 2020;190:2251-66. [PMID: 32712019 DOI: 10.1016/j.ajpath.2020.07.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
91 Wu N, Meng F, Zhou T, Han Y, Kennedy L, Venter J, Francis H, DeMorrow S, Onori P, Invernizzi P, Bernuzzi F, Mancinelli R, Gaudio E, Franchitto A, Glaser S, Alpini G. Prolonged darkness reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miR-200b down-regulation. FASEB J 2017;31:4305-24. [PMID: 28634212 DOI: 10.1096/fj.201700097R] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 6.4] [Reference Citation Analysis]
92 Bigaeva E, Gore E, Mutsaers HAM, Oosterhuis D, Kim YO, Schuppan D, Bank RA, Boersema M, Olinga P. Exploring organ-specific features of fibrogenesis using murine precision-cut tissue slices. Biochim Biophys Acta Mol Basis Dis 2020;1866:165582. [PMID: 31676376 DOI: 10.1016/j.bbadis.2019.165582] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
93 Gudnason HO, Björnsson ES. Secondary sclerosing cholangitis in critically ill patients: current perspectives. Clin Exp Gastroenterol 2017;10:105-11. [PMID: 28694703 DOI: 10.2147/CEG.S115518] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
94 Popov Y, Sverdlov DY, Sharma AK, Bhaskar KR, Li S, Freitag TL, Lee J, Dieterich W, Melino G, Schuppan D. Tissue transglutaminase does not affect fibrotic matrix stability or regression of liver fibrosis in mice. Gastroenterology 2011;140:1642-52. [PMID: 21277850 DOI: 10.1053/j.gastro.2011.01.040] [Cited by in Crossref: 87] [Cited by in F6Publishing: 85] [Article Influence: 7.9] [Reference Citation Analysis]
95 Yoshida S, Ikenaga N, Liu SB, Peng ZW, Chung J, Sverdlov DY, Miyamoto M, Kim YO, Ogawa S, Arch RH, Schuppan D, Popov Y. Extrahepatic platelet-derived growth factor-β, delivered by platelets, promotes activation of hepatic stellate cells and biliary fibrosis in mice. Gastroenterology 2014;147:1378-92. [PMID: 25173753 DOI: 10.1053/j.gastro.2014.08.038] [Cited by in Crossref: 83] [Cited by in F6Publishing: 80] [Article Influence: 10.4] [Reference Citation Analysis]
96 Scrushy M, O'Brien A, Glaser S. Recent advances in understanding bile duct remodeling and fibrosis. F1000Res 2018;7:F1000 Faculty Rev-1165. [PMID: 30109019 DOI: 10.12688/f1000research.14578.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
97 An P, Wei LL, Zhao S, Sverdlov DY, Vaid KA, Miyamoto M, Kuramitsu K, Lai M, Popov YV. Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis. Nat Commun 2020;11:2362. [PMID: 32398673 DOI: 10.1038/s41467-020-16092-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis]
98 Dyson JK, Hirschfield GM, Adams DH, Beuers U, Mann DA, Lindor KD, Jones DE. Novel therapeutic targets in primary biliary cirrhosis. Nat Rev Gastroenterol Hepatol. 2015;12:147-158. [PMID: 25645973 DOI: 10.1038/nrgastro.2015.12] [Cited by in Crossref: 81] [Cited by in F6Publishing: 75] [Article Influence: 11.6] [Reference Citation Analysis]
99 Guicciardi ME, Trussoni CE, Krishnan A, Bronk SF, Lorenzo Pisarello MJ, O'Hara SP, Splinter PL, Gao Y, Vig P, Revzin A, LaRusso NF, Gores GJ. Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice. J Hepatol 2018;69:676-86. [PMID: 29802947 DOI: 10.1016/j.jhep.2018.05.018] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 12.8] [Reference Citation Analysis]
100 Liu SB, Ikenaga N, Peng ZW, Sverdlov DY, Greenstein A, Smith V, Schuppan D, Popov Y. Lysyl oxidase activity contributes to collagen stabilization during liver fibrosis progression and limits spontaneous fibrosis reversal in mice. FASEB J 2016;30:1599-609. [PMID: 26700732 DOI: 10.1096/fj.14-268425] [Cited by in Crossref: 94] [Cited by in F6Publishing: 95] [Article Influence: 13.4] [Reference Citation Analysis]
101 Sokolović A, van Roomen CP, Ottenhoff R, Scheij S, Hiralall JK, Claessen N, Aten J, Oude Elferink RP, Groen AK, Sokolović M. Fasting reduces liver fibrosis in a mouse model for chronic cholangiopathies. Biochim Biophys Acta 2013;1832:1482-91. [PMID: 23707514 DOI: 10.1016/j.bbadis.2013.05.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
102 Wang X, Hausding M, Weng S, Kim YO, Steven S, Klein T, Daiber A, Schuppan D. Gliptins Suppress Inflammatory Macrophage Activation to Mitigate Inflammation, Fibrosis, Oxidative Stress, and Vascular Dysfunction in Models of Nonalcoholic Steatohepatitis and Liver Fibrosis. Antioxidants & Redox Signaling 2018;28:87-109. [DOI: 10.1089/ars.2016.6953] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
103 Fernández-Ramos D, Fernández-Tussy P, Lopitz-Otsoa F, Gutiérrez-de-Juan V, Navasa N, Barbier-Torres L, Zubiete-Franco I, Simón J, Fernández AF, Arbelaiz A, Aransay AM, Lavín JL, Beraza N, Perugorria MJ, Banales JM, Villa E, Fraga MF, Anguita J, Avila MA, Berasain C, Iruzibieta P, Crespo J, Lu SC, Varela-Rey M, Mato JM, Delgado TC, Martínez-Chantar ML. MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosis. Cell Death Dis 2018;9:958. [PMID: 30237481 DOI: 10.1038/s41419-018-1014-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
104 Popov Y, Patsenker E, Bauer M, Niedobitek E, Schulze-Krebs A, Schuppan D. Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NFkappaB. J Biol Chem. 2006;281:15090-15098. [PMID: 16489207 DOI: 10.1074/jbc.m600030200] [Cited by in Crossref: 75] [Cited by in F6Publishing: 41] [Article Influence: 4.7] [Reference Citation Analysis]
105 Territo PR, Maluccio M, Riley AA, McCarthy BP, Fletcher J, Tann M, Saxena R, Skill NJ. Evaluation of 11C-acetate and 18F-FDG PET/CT in mouse multidrug resistance gene-2 deficient mouse model of hepatocellular carcinoma. BMC Med Imaging 2015;15:15. [PMID: 25981587 DOI: 10.1186/s12880-015-0058-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
106 Weng SY, Wang X, Vijayan S, Tang Y, Kim YO, Padberg K, Regen T, Molokanova O, Chen T, Bopp T, Schild H, Brombacher F, Crosby JR, McCaleb ML, Waisman A, Bockamp E, Schuppan D. IL-4 Receptor Alpha Signaling through Macrophages Differentially Regulates Liver Fibrosis Progression and Reversal. EBioMedicine 2018;29:92-103. [PMID: 29463471 DOI: 10.1016/j.ebiom.2018.01.028] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 9.3] [Reference Citation Analysis]
107 Pollheimer MJ, Racedo S, Mikels-Vigdal A, Marshall D, Bowlus C, Lackner C, Madl T, Karlsen TH, Hov JR, Lyman SK, Adamkewicz J, Smith V, Moreau E, Zollner G, Eide TJ, Stojakovic T, Scharnagl H, Gruber HJ, Stauber RE, Trauner M, Fickert P. Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis. J Hepatol 2018;69:368-77. [PMID: 29709678 DOI: 10.1016/j.jhep.2018.04.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
108 Yang A, Yan X, Xu H, Fan X, Zhang M, Huang T, Li W, Chen W, Jia J, You H. Selective depletion of hepatic stellate cells-specific LOXL1 alleviates liver fibrosis. FASEB J 2021;35:e21918. [PMID: 34569648 DOI: 10.1096/fj.202100374R] [Reference Citation Analysis]
109 Pollheimer MJ, Fickert P, Stieger B. Chronic cholestatic liver diseases: clues from histopathology for pathogenesis. Mol Aspects Med. 2014;37:35-56. [PMID: 24141039 DOI: 10.1016/j.mam.2013.10.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
110 Angioni R, Calì B, Vigneswara V, Crescenzi M, Merino A, Sánchez-Rodríguez R, Liboni C, Hoogduijn MJ, Newsome PN, Muraca M, Russo FP, Viola A. Administration of Human MSC-Derived Extracellular Vesicles for the Treatment of Primary Sclerosing Cholangitis: Preclinical Data in MDR2 Knockout Mice. Int J Mol Sci 2020;21:E8874. [PMID: 33238629 DOI: 10.3390/ijms21228874] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
111 Li E, Lin L, Chen CW, Ou DL. Mouse Models for Immunotherapy in Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E1800. [PMID: 31731753 DOI: 10.3390/cancers11111800] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
112 Ikenaga N, Liu SB, Sverdlov DY, Yoshida S, Nasser I, Ke Q, Kang PM, Popov Y. A new Mdr2(-/-) mouse model of sclerosing cholangitis with rapid fibrosis progression, early-onset portal hypertension, and liver cancer. Am J Pathol 2015;185:325-34. [PMID: 25478810 DOI: 10.1016/j.ajpath.2014.10.013] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
113 Gonzalez-Sanchez E, El Mourabit H, Jager M, Clavel M, Moog S, Vaquero J, Ledent T, Cadoret A, Gautheron J, Fouassier L, Wendum D, Chignard N, Housset C. Cholangiopathy aggravation is caused by VDR ablation and alleviated by VDR-independent vitamin D signaling in ABCB4 knockout mice. Biochim Biophys Acta Mol Basis Dis 2021;1867:166067. [PMID: 33418034 DOI: 10.1016/j.bbadis.2020.166067] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 Crespo Yanguas S, Cogliati B, Willebrords J, Maes M, Colle I, van den Bossche B, de Oliveira CP, Andraus W, Alves VA, Leclercq I. Experimental models of liver fibrosis. Arch Toxicol. 2016;90:1025-1048. [PMID: 26047667 DOI: 10.1007/s00204-015-1543-4] [Cited by in Crossref: 108] [Cited by in F6Publishing: 107] [Article Influence: 15.4] [Reference Citation Analysis]
115 Patsenker E, Schneider V, Ledermann M, Saegesser H, Dorn C, Hellerbrand C, Stickel F. Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. J Hepatol. 2011;55:388-398. [PMID: 21168455 DOI: 10.1016/j.jhep.2010.10.044] [Cited by in Crossref: 83] [Cited by in F6Publishing: 85] [Article Influence: 6.9] [Reference Citation Analysis]
116 Vogel KR, Kennedy AA, Whitehouse LA, Gibson KM. Therapeutic hepatocyte transplant for inherited metabolic disorders: functional considerations, recent outcomes and future prospects. J Inherit Metab Dis 2014;37:165-76. [PMID: 24085555 DOI: 10.1007/s10545-013-9656-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
117 Sokolović A, Rodriguez-ortigosa CM, Bloemendaal LT, Oude Elferink RP, Prieto J, Bosma PJ. Insulin-like growth factor 1 enhances bile-duct proliferation and fibrosis in Abcb4−/− mice. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2013;1832:697-704. [DOI: 10.1016/j.bbadis.2013.02.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
118 Karlsen TH, Schrumpf E, Boberg KM. Genetic epidemiology of primary sclerosing cholangitis. World J Gastroenterol 2007; 13(41): 5421-5431 [PMID: 17907284 DOI: 10.3748/wjg.v13.i41.5421] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 39] [Article Influence: 3.5] [Reference Citation Analysis]
119 Lohwasser C, Neureiter D, Popov Y, Bauer M, Schuppan D. Role of the receptor for advanced glycation end products in hepatic fibrosis. World J Gastroenterol 2009; 15(46): 5789-5798 [PMID: 19998499 DOI: 10.3748/wjg.15.5789] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
120 Manchanda M, Das P, Gahlot GPS, Singh R, Roeb E, Roderfeld M, Datta Gupta S, Saraya A, Pandey RM, Chauhan SS. Cathepsin L and B as Potential Markers for Liver Fibrosis: Insights From Patients and Experimental Models. Clin Transl Gastroenterol 2017;8:e99. [PMID: 28617446 DOI: 10.1038/ctg.2017.25] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
121 Joshi N, Kopec AK, Cline-Fedewa H, Luyendyk JP. Lymphocytes contribute to biliary injury and fibrosis in experimental xenobiotic-induced cholestasis. Toxicology 2017;377:73-80. [PMID: 28049044 DOI: 10.1016/j.tox.2016.12.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
122 Shetty S, Boyer JL. Bile acid metabolism and T cell responses in cholangiopathy: Not one-way traffic. J Hepatol 2019;71:657-9. [PMID: 31447221 DOI: 10.1016/j.jhep.2019.07.012] [Reference Citation Analysis]
123 Hammad S, Cavalcanti E, Werle J, Caruso ML, Dropmann A, Ignazzi A, Ebert MP, Dooley S, Giannelli G. Galunisertib modifies the liver fibrotic composition in the Abcb4Ko mouse model. Arch Toxicol 2018;92:2297-309. [PMID: 29808285 DOI: 10.1007/s00204-018-2231-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
124 Nakken KE, Nygard S, Haaland TK, Berge KE, Ødegaard A, Labori KJ, Raeder MG. Gene expression profiles reflect sclerosing cholangitis activity in abcb4 (-/-) mice. Scand J Gastroenterol 2009;44:211-8. [PMID: 18785065 DOI: 10.1080/00365520802400867] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
125 Ferreira-Gonzalez S, Rodrigo-Torres D, Gadd VL, Forbes SJ. Cellular Senescence in Liver Disease and Regeneration. Semin Liver Dis 2021;41:50-66. [PMID: 33764485 DOI: 10.1055/s-0040-1722262] [Reference Citation Analysis]
126 Fickert P, Pollheimer MJ, Österreicher CH, Trauner M. Animal Models of Cholestasis. Animal Models for the Study of Human Disease. Elsevier; 2013. pp. 331-49. [DOI: 10.1016/b978-0-12-415894-8.00015-4] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
127 Gore E, Bigaeva E, Oldenburger A, Kim YO, Rippmann JF, Schuppan D, Boersema M, Olinga P. PI3K inhibition reduces murine and human liver fibrogenesis in precision-cut liver slices. Biochem Pharmacol 2019;169:113633. [PMID: 31494146 DOI: 10.1016/j.bcp.2019.113633] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
128 Nesset CK, Kong XY, Damme M, Schjalm C, Roos N, Løberg EM, Eskild W. Age-dependent development of liver fibrosis in Glmp (gt/gt) mice. Fibrogenesis Tissue Repair 2016;9:5. [PMID: 27141234 DOI: 10.1186/s13069-016-0042-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
129 Andress EJ, Nicolaou M, McGeoghan F, Linton KJ. ABCB4 missense mutations D243A, K435T, G535D, I490T, R545C, and S978P significantly impair the lipid floppase and likely predispose to secondary pathologies in the human population. Cell Mol Life Sci. 2017;74:2513-2524. [PMID: 28220208 DOI: 10.1007/s00018-017-2472-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
130 Zhang CY, Yuan WG, He P, Lei JH, Wang CX. Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets. World J Gastroenterol. 2016;22:10512-10522. [PMID: 28082803 DOI: 10.3748/wjg.v22.i48.10512.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
131 Hauff P, Gottwald U, Ocker M. Early to Phase II drugs currently under investigation for the treatment of liver fibrosis. Expert Opin Investig Drugs. 2015;24:309-327. [PMID: 25547844 DOI: 10.1517/13543784.2015.997874] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
132 Ernst TM, Schwinge D, Raabe N, Daubmann A, Kaul MG, Adam G, Schramm C, Ittrich H. Imaging of the murine biliopancreatic tract at 7 tesla: Technique and results in a model of primary sclerosing cholangitis: Imaging the Murine Biliopancreatic Tract. J Magn Reson Imaging 2014;40:1355-64. [DOI: 10.1002/jmri.24475] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
133 Taylor AE, Carey AN, Kudira R, Lages CS, Shi T, Lam S, Karns R, Simmons J, Shanmukhappa K, Almanan M, Chougnet CA, Miethke AG. Interleukin 2 Promotes Hepatic Regulatory T Cell Responses and Protects From Biliary Fibrosis in Murine Sclerosing Cholangitis. Hepatology 2018;68:1905-21. [PMID: 29698570 DOI: 10.1002/hep.30061] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
134 Eckert C, Kim YO, Julich H, Heier EC, Klein N, Krause E, Tschernig T, Kornek M, Lammert F, Schuppan D, Lukacs-Kornek V. Podoplanin discriminates distinct stromal cell populations and a novel progenitor subset in the liver. Am J Physiol Gastrointest Liver Physiol 2016;310:G1-12. [PMID: 26564718 DOI: 10.1152/ajpgi.00344.2015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
135 Hall C, Ehrlich L, Meng F, Invernizzi P, Bernuzzi F, Lairmore TC, Alpini G, Glaser S. Inhibition of microRNA-24 increases liver fibrosis by enhanced menin expression in Mdr2-/- mice. J Surg Res 2017;217:160-9. [PMID: 28602220 DOI: 10.1016/j.jss.2017.05.020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
136 Weber ND, Odriozola L, Martínez-García J, Ferrer V, Douar A, Bénichou B, González-Aseguinolaza G, Smerdou C. Gene therapy for progressive familial intrahepatic cholestasis type 3 in a clinically relevant mouse model. Nat Commun 2019;10:5694. [PMID: 31836711 DOI: 10.1038/s41467-019-13614-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
137 Peng ZW, Rothweiler S, Wei G, Ikenaga N, Liu SB, Sverdlov DY, Vaid KA, Longhi MS, Kuang M, Robson SC, Popov YV. The ectonucleotidase ENTPD1/CD39 limits biliary injury and fibrosis in mouse models of sclerosing cholangitis. Hepatol Commun 2017;1:957-72. [PMID: 29404503 DOI: 10.1002/hep4.1084] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
138 Kennedy L, Meadows V, Kyritsi K, Pham L, Kundu D, Kulkarni R, Cerritos K, Demieville J, Hargrove L, Glaser S, Zhou T, Jaeger V, Alpini G, Francis H. Amelioration of Large Bile Duct Damage by Histamine-2 Receptor Vivo-Morpholino Treatment. Am J Pathol 2020;190:1018-29. [PMID: 32142732 DOI: 10.1016/j.ajpath.2020.01.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
139 Folseraas T, Karlsen TH. To MMP or not to MMP: a role for matrix metalloproteinase 3 in primary sclerosing cholangitis?: Editorial. Liver International 2011;31:751-4. [DOI: 10.1111/j.1478-3231.2011.02471.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
140 Bowlus CL. Cutting edge issues in primary sclerosing cholangitis. Clin Rev Allergy Immunol 2011;41:139-50. [PMID: 21170605 DOI: 10.1007/s12016-010-8221-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
141 Nalapareddy P, Schüngel S, Hong JY, Manns MP, Jaeschke H, Vogel A. The BH3-only protein bid does not mediate death-receptor-induced liver injury in obstructive cholestasis. Am J Pathol. 2009;175:1077-1085. [PMID: 19661444 DOI: 10.2353/ajpath.2009.090304] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
142 Sokolović A, Sokolović M, Boers W, Elferink RP, Bosma PJ. Insulin-like growth factor binding protein 5 enhances survival of LX2 human hepatic stellate cells. Fibrogenesis Tissue Repair. 2010;3:3. [PMID: 20163708 DOI: 10.1186/1755-1536-3-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.7] [Reference Citation Analysis]
143 Brown ZJ, Heinrich B, Greten TF. Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research. Nat Rev Gastroenterol Hepatol 2018;15:536-54. [DOI: 10.1038/s41575-018-0033-6] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 17.5] [Reference Citation Analysis]
144 Amirneni S, Haep N, Gad MA, Soto-Gutierrez A, Squires JE, Florentino RM. Molecular overview of progressive familial intrahepatic cholestasis. World J Gastroenterol 2020; 26(47): 7470-7484 [PMID: 33384548 DOI: 10.3748/wjg.v26.i47.7470] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
145 Li X, Liu R, Yang J, Sun L, Zhang L, Jiang Z, Puri P, Gurley EC, Lai G, Tang Y, Huang Z, Pandak WM, Hylemon PB, Zhou H. The role of long noncoding RNA H19 in gender disparity of cholestatic liver injury in multidrug resistance 2 gene knockout mice. Hepatology 2017;66:869-84. [PMID: 28271527 DOI: 10.1002/hep.29145] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 10.2] [Reference Citation Analysis]
146 Wei G, An P, Vaid KA, Nasser I, Huang P, Tan L, Zhao S, Schuppan D, Popov YV. Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer. Am J Physiol Gastrointest Liver Physiol 2020;318:G174-88. [PMID: 31630534 DOI: 10.1152/ajpgi.00041.2019] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
147 Buko V, Belonovskaya E, Naruta E, Lukivskaya O, Kanyuka O, Zhuk O, Kranc R, Stoika R, Sybirna N. Pituitary tumor transforming gene as a novel regulatory factor of liver fibrosis. Life Sci 2015;132:34-40. [PMID: 25936962 DOI: 10.1016/j.lfs.2015.04.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
148 Kwong GA, von Maltzahn G, Murugappan G, Abudayyeh O, Mo S, Papayannopoulos IA, Sverdlov DY, Liu SB, Warren AD, Popov Y, Schuppan D, Bhatia SN. Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease. Nat Biotechnol 2013;31:63-70. [PMID: 23242163 DOI: 10.1038/nbt.2464] [Cited by in Crossref: 116] [Cited by in F6Publishing: 101] [Article Influence: 11.6] [Reference Citation Analysis]
149 Weber SN, Wasmuth HE. Liver fibrosis: from animal models to mapping of human risk variants. Best Pract Res Clin Gastroenterol. 2010;24:635-646. [PMID: 20955966 DOI: 10.1016/j.bpg.2010.07.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
150 Philips GM, Chan IS, Swiderska M, Schroder VT, Guy C, Karaca GF, Moylan C, Venkatraman T, Feuerlein S, Syn WK, Jung Y, Witek RP, Choi S, Michelotti GA, Rangwala F, Merkle E, Lascola C, Diehl AM. Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer. PLoS One. 2011;6:e23943. [PMID: 21912653 DOI: 10.1371/journal.pone.0023943] [Cited by in Crossref: 110] [Cited by in F6Publishing: 113] [Article Influence: 10.0] [Reference Citation Analysis]
151 de Meijer VE, Le HD, Meisel JA, Akhavan Sharif MR, Pan A, Nosé V, Puder M. Dietary fat intake promotes the development of hepatic steatosis independently from excess caloric consumption in a murine model. Metabolism. 2010;59:1092-1105. [PMID: 20060143 DOI: 10.1016/j.metabol.2009.11.006] [Cited by in Crossref: 67] [Cited by in F6Publishing: 66] [Article Influence: 5.6] [Reference Citation Analysis]
152 Freund C, Gotthardt DN. Vitamin A deficiency in chronic cholestatic liver disease: Is vitamin A therapy beneficial? Liver Int 2017;37:1752-8. [PMID: 28371374 DOI: 10.1111/liv.13433] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
153 Kunst RF, Niemeijer M, van der Laan LJW, Spee B, van de Graaf SFJ. From fatty hepatocytes to impaired bile flow: Matching model systems for liver biology and disease. Biochem Pharmacol 2020;180:114173. [PMID: 32717228 DOI: 10.1016/j.bcp.2020.114173] [Reference Citation Analysis]
154 Patsenker E, Popov Y, Stickel F, Jonczyk A, Goodman SL, Schuppan D. Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology. 2008;135:660-670. [PMID: 18538673 DOI: 10.1053/j.gastro.2008.04.009] [Cited by in Crossref: 133] [Cited by in F6Publishing: 144] [Article Influence: 9.5] [Reference Citation Analysis]
155 Leonhardt S, Veltzke-Schlieker W, Adler A, Schott E, Hetzer R, Schaffartzik W, Tryba M, Neuhaus P, Seehofer D. Trigger mechanisms of secondary sclerosing cholangitis in critically ill patients. Crit Care 2015;19:131. [PMID: 25886728 DOI: 10.1186/s13054-015-0861-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
156 L Ng KV, Nguyn LT. The role of vitamin d in primary biliary cirrhosis: possible genetic and cell signaling mechanisms. Gastroenterol Res Pract. 2013;2013:602321. [PMID: 23589715 DOI: 10.1155/2013/602321] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
157 Freitag TL, Rietdijk S, Junker Y, Popov Y, Bhan AK, Kelly CP, Terhorst C, Schuppan D. Gliadin-primed CD4+CD45RBlowCD25- T cells drive gluten-dependent small intestinal damage after adoptive transfer into lymphopenic mice. Gut 2009;58:1597-605. [PMID: 19671544 DOI: 10.1136/gut.2009.186361] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
158 Chowdhury S, Chen Y, Yao TW, Ajami K, Wang XM, Popov Y, Schuppan D, Bertolino P, McCaughan GW, Yu DM, Gorrell MD. Regulation of dipeptidyl peptidase 8 and 9 expression in activated lymphocytes and injured liver. World J Gastroenterol 2013; 19(19): 2883-2893 [PMID: 23704821 DOI: 10.3748/wjg.v19.i19.2883] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
159 Fosby B, Karlsen TH, Melum E. Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. World J Gastroenterol 2012; 18(1): 1-15 [PMID: 22228965 DOI: 10.3748/wjg.v18.i1.1] [Cited by in CrossRef: 80] [Cited by in F6Publishing: 63] [Article Influence: 8.0] [Reference Citation Analysis]
160 Palladini G, Ferrigno A, Richelmi P, Perlini S, Vairetti M. Role of matrix metalloproteinases in cholestasis and hepatic ischemia/reperfusion injury: A review. World J Gastroenterol 2015; 21(42): 12114-12124 [PMID: 26576096 DOI: 10.3748/wjg.v21.i42.12114] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
161 Latasa MU, Gil-Puig C, Fernández-Barrena MG, Rodríguez-Ortigosa CM, Banales JM, Urtasun R, Goñi S, Méndez M, Arcelus S, Juanarena N, Recio JA, Lotersztajn S, Prieto J, Berasain C, Corrales FJ, Lecanda J, Avila MA. Oral methylthioadenosine administration attenuates fibrosis and chronic liver disease progression in Mdr2-/- mice. PLoS One 2010;5:e15690. [PMID: 21209952 DOI: 10.1371/journal.pone.0015690] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
162 Boursier J, Louvet A. Liver fibrogenesis and genetic factors. Clin Res Hepatol Gastroenterol 2011;35 Suppl 1:S3-9. [PMID: 21742298 DOI: 10.1016/S2210-7401(11)70002-X] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
163 Trautwein C, Friedman SL, Schuppan D, Pinzani M. Hepatic fibrosis: Concept to treatment. J Hepatol. 2015;62:S15-24. [PMID: 25920084 DOI: 10.1016/j.jhep.2015.02.039] [Cited by in Crossref: 350] [Cited by in F6Publishing: 329] [Article Influence: 58.3] [Reference Citation Analysis]
164 Pollheimer MJ, Trauner M, Fickert P. Will we ever model PSC? - "it's hard to be a PSC model!". Clin Res Hepatol Gastroenterol. 2011;35:792-804. [PMID: 21703962 DOI: 10.1016/j.clinre.2011.04.014] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
165 Fuji H, Miller G, Nishio T, Koyama Y, Lam K, Zhang V, Loomba R, Brenner D, Kisseleva T. The role of Mesothelin signaling in Portal Fibroblasts in the pathogenesis of cholestatic liver fibrosis. Front Mol Biosci 2021;8:790032. [PMID: 34966784 DOI: 10.3389/fmolb.2021.790032] [Reference Citation Analysis]
166 Kyritsi K, Meng F, Zhou T, Wu N, Venter J, Francis H, Kennedy L, Onori P, Franchitto A, Bernuzzi F, Invernizzi P, McDaniel K, Mancinelli R, Alvaro D, Gaudio E, Alpini G, Glaser S. Knockdown of Hepatic Gonadotropin-Releasing Hormone by Vivo-Morpholino Decreases Liver Fibrosis in Multidrug Resistance Gene 2 Knockout Mice by Down-Regulation of miR-200b. Am J Pathol 2017;187:1551-65. [PMID: 28502477 DOI: 10.1016/j.ajpath.2017.03.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
167 Cheng L, Tian F, Tian F, Tang L, Chen G, Luo Z, Ren J, Wang S. Repression of Farnesoid X receptor contributes to biliary injuries of liver grafts through disturbing cholangiocyte bile acid transport. Am J Transplant. 2013;13:3094-3102. [PMID: 24266967 DOI: 10.1111/ajt.12479] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]